The L858R mutation at the EGFR locus is one of the most common mutations in non-small-cell lung cancer (NSCLC) patients and can be targeted by EGFR tyrosine kinase inhibitors (EGFR-TKIs)38. Here, EGFR is linked to non-small cell lung carcinoma.